These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 35421324)

  • 21. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
    Tanaka H; Mukai J; Kushibiki K; Mizushima S; Maeda K; Fujimoto Y; Sawada R; Oda M; Okuda H; Yamaki M; Hashiguchi S; Kawai I; Kawaguchi I; Masuda N; Matsushita H
    Vaccine; 2023 Jan; 41(2):365-371. PubMed ID: 36460533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 26. Investigation of SARS-CoV-2 antibody levels after COVID-19 vaccine in chronic hepatitis B patients.
    Kinikli S; Afsar FE; Dursun AD; Aksoy A; Karahan G; Cesur S; Hatipoglu ÇA; Ertem GT; Erdinc FS; Urtimur U
    Bratisl Lek Listy; 2024; 125(6):376-381. PubMed ID: 38757595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study.
    Mochizuki T; Hori T; Yano K; Ikari K; Okazaki K
    Intern Med; 2022 Apr; 61(8):1139-1143. PubMed ID: 35185050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
    Mok CKP; Cohen CA; Cheng SMS; Chen C; Kwok KO; Yiu K; Chan TO; Bull M; Ling KC; Dai Z; Ng SS; Lui GC; Wu C; Amarasinghe GK; Leung DW; Wong SYS; Valkenburg SA; Peiris M; Hui DS
    Respirology; 2022 Apr; 27(4):301-310. PubMed ID: 34820940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of antibody response to CoronaVac vaccine.
    Fonseca MHG; de Souza TFG; de Carvalho Araújo FM; de Andrade LOM
    J Med Virol; 2022 May; 94(5):2139-2148. PubMed ID: 35060174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose.
    Filardi BA; Monteiro VS; Schwartzmann PV; do Prado Martins V; Zucca LER; Baiocchi GC; Malik AA; Silva J; Hahn AM; Chen NFG; Pham K; Pérez-Then E; Miric M; Brache V; Cochon L; Larocca RA; Mendez RDR; Bardini Silveira D; Pinto AR; Croda J; Yildirim I; Omer SB; Ko AI; Vermund SH; Grubaugh ND; Iwasaki A; Lucas C; ; Vogels CBF; Breban M; Koch TR; Chaguza C; Tikhonova I; Castaldi C; Mane S; De Kumar B; Ferguson D; Kerantzas N; Peaper D; Landry ML; Schulz W
    Sci Transl Med; 2023 Feb; 15(683):eade6023. PubMed ID: 36791210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
    Mazzola A; Todesco E; Drouin S; Hazan F; Marot S; Thabut D; Varnous S; Soulié C; Barrou B; Marcelin AG; Conti F
    Clin Infect Dis; 2022 Mar; 74(6):1093-1096. PubMed ID: 34166499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
    Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
    J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.